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12 months follow-upBackground: The aim of this study was to compare the 12-month clinical outcomes of patients treated with
Magmaris or Orsiro. Second generation drug-eluting absorbable metal scaffold Magmaris (Dreams 2G) has
proved to be safe and effective in the BIOSOLVE-II study. Similarly, biodegradable polymer sirolimus-eluting
stent, Orsiro has shown notable clinical results even in all-comer populations.
Methods: Magmaris group patients were taken from the BIOSOLVE-II and BIOSOLVE-III trials, while the patients
from Orsiro group were enrolled in BIOFLOW-II trial. The primary outcome was explored using a time-to-event
assessment of the unadjusted clinical outcomes for target lesion failure (TLF) at 12 months, followed by a multi-
variate analysis adjusting for all the significantly different covariates between the groups.
Results: The study population consisted of 482 patients (521 lesions), 184 patients (189 lesions) in Magmaris
group and 298 patients (332 lesions) in Orsiro group. The mean age was 65.5 ± 10.8 and 62.7 ± 10.4 years in
Magmaris and Orsiro groups, respectively (p = 0.005). Magmaris and Orsiro unadjusted TLF rates were 6.0
and 6.4% with no significant difference between the groups (p = 0.869). In the multivariate analysis, there
were nomeaningful differences betweenMagmaris and Orsiro groups. Finally, none of the groups presented de-
vice thrombosis cases at 12 months.
Conclusion: At 12 months there were no significant differences between Magmaris and Orsiro groups neither in
the unadjusted assessment nor in themultivariate analysis for target lesion failure. These results should be taken
as hypothesis generating and may warrant a head to head comparison on a randomized fashion.
© 2019 Published by Elsevier B.V.ardiology, MedStar Cardiovascular Research Network, MedStar Washington Hospital Center, East Building - Room 5121, 110
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Percutaneous coronary interventions with metallic drug-eluting
stents (DES) have proven to be safe and effective inmost clinical scenar-
ios [1]. The adoption of these devices, however, aroused other issues
such as stent thrombosis (ST) [2]. The bioresorbable scaffold (BRS) con-
cept fostered the idea that thesematters would beminimized [3]. How-
ever, this promise has not been fulfilled by the first-generation
polymeric BRS since they have been associated with an increased rate
of ST at all-time points compared to metallic DES [4,5]. Subsequently,
newer metallic BRS platforms such as the second-generation drug-
eluting Resorbable Magnesium Scaffold (RMS), Magmaris (Dreams
2G), have been introduced, and short- to mid-term results are promis-
ing [6,7]. Magmaris has proved to be safe and effective in the
BIOSOLVE-II trial and in the long-term follow-up [7]. Likewise, the ultra-
thin, biodegradable polymer sirolimus-eluting stent (Orsiro) has shown
good clinical results in all-comer populations [9,10]. There has not yet
been a comparison between this second-generation RMS and a metallic
DES. The aim of this study is to compare the 12-month clinical outcomes
of patients treated with Magmaris or Orsiro.
2. Methods
2.1. Study design and population
The patients included in the analysis were taken from BIOSOLVE-II,
BIOSOLVE-III, and BIOFLOW-II trials. The Magmaris group was com-
posed of the patients from 2 Magmaris registries (BIOSOLVE-II and
BIOSOLVE-III trials) [6,7], while the Orsiro group was composed of the
patients from 1 Orsiro randomized control trial (RCT) (BIOFLOW-II
trial) [9]. The study designs for these trials have been previously pub-
lished elsewhere [6–9]. The inclusion criteria were similar (otherwise
indicated): [1] stable or unstable angina, documented silent ischemia
(BIOFLOW II also included patients with clinically drivenmyocardial in-
farction (CDMI)); [2] Lesion length was ≤26 mm for BIOFLOW-II and
≤21mm for BIOSOLVE-II and BIOSOLVE-III; and [3] Reference target ves-
sel diameter ≥2.25 to 4.0 mm, ≥2.2 to 3.8 mm, and ≥2.7 to 3.8 mm for
BIOFLOW-II, BIOSOLVE-II, and BISOLVE-III, respectively. The exclusion
criteria were [1] left ventricle ejection fraction ≤30%; [2] presence of
thrombus in the target vessel (TV); [3] TV with severe calcification;
[4] Target Lesion (TL) is a bifurcation lesion involving a side branch
N2.0 mm in diameter; [5] three-vessel coronary artery disease (CAD)
at time of the index procedure; [6] TL is located in or supplied by an ar-
terial or venous bypass graft; [7] unprotected left main coronary artery
disease; [8]MI ≤72h before the index procedure; and [9] ostial target le-
sions in BIOSOLVE-II and BIOSOLVE-III. The lists of all inclusion and ex-
clusion criteria for the 3 studies are available at ClinicalTrials.gov
(NCT01356888, NCT01960504, and NCT02716220 for BIOFLOW-II,
BIOSOLVE-II, and BIOSOLVE-III, respectively).
2.2. Devices in the study
The specifications and details of each device in this study (i.e.
Magmaris, Orsiro, and Xience) were previously described [6–9].
2.3. Procedure and medications
In the BIOFLOW-II trial, the patients were allocated in the Orsiro or
Xience groups. Pre-dilation was recommended but not mandatory.
The use of N1 study device per TL was limited to bailout situations. In
BIOSOLVE-II and -III, pre-dilation was mandatory before Magmaris de-
ployment; post-dilation was not (but advised). The use of N1 scaffold
per TL was also limited to bailout situations. In case of study device fail-
ure, in BIOSOLVE-II and -III trials, an Orsiro stent was used.
The concomitant medications in all studies were unfractionated
heparin or low-molecular-weight heparin during the index procedurePlease cite this article as: A. Hideo-Kajita, H.M. Garcia-Garcia, P. Kolm, et al
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acetylsalicylic acid (ASA) ≥3 days before the procedure dose of
75–100 mg (pre-procedure loading dose of 250–500 mg) and
clopidogrel loading dose of 300–600 mg 6 h before index procedure
(except for those already in use of 75 mg/day for ≥7 days). Dual anti-
platelet therapy (DAPT) regimen was given to all patients for at least
6 months after device implantation.2.4. Outcomes and definitions
Target lesion failure (TLF) at 12 months was the primary out-
come. TLF was defined as a composite of cardiac death, target vessel
myocardial infarction (TVMI), and clinically driven target lesion re-
vascularization (CD-TLR) in the BIOFLOW-II and BIOSOLVE-II and
-III trials [6–9].
The secondary outcomes included the individual components of the
primary outcome plus death, anymyocardial infarction (MI), any target
lesion revascularization (TLR), any target vessel revascularization
(TVR), clinically driven TVR (CD-TVR), target vessel failure (TVF), and
ST for each group. TVF was defined as the composite of cardiac death,
target-vessel MI, and CD-TVR.
Previously, MI was defined following the Society for Cardiovascular
Angiography and Interventions (SCAI) consensus in the BIOSOLVE-II
and -III trials. In BIOFLOW-II trial, the Third Universal Definition of MI
and Academic Research Consortium (ARC) guidelines definitions were
used [11–13]. The present analysis defined MI in consonance to the
Third Universal Definition of MI, since the variable that was also avail-
able in BIOSOLVE-II and -III the patient level data [12].
TLR, TVR and ST were defined in accordance with ARC guidelines in
BIOFLOW-II, BIOSOLVE-II and -III trials [11].2.5. Statistical analysis
Means and standard deviations were used to present continuous
variables, and frequencies and percentages for categorical variables
in the following tables. Baseline characteristics, procedure character-
istics, and the unadjusted clinical outcomes differences between the
Magmaris and Orsiro groups were compared with standardized
differences expressed in p-values. The p-value was considered statis-
tically significant when p b 0.05, otherwise indicated. The unadjusted
clinical outcomes time-to-event assessment for TLF was modeled as
a mixed effects Weibull survival distribution, incorporating different
sites within the same country as random effects [14,15].
Kaplan-Meier curves were constructed for the unadjusted survival
functions of the Magmaris vs. Orsiro devices. The statistical analysis
was performed using Stata v.15 (Stata Corp, College Station,
TX, USA).2.6. Multivariate analysis
The multivariate analysis (MVA) for the primary outcome was per-
formed in 2 steps. TLF was set as the main outcome variable (depen-
dent). The first step included all the significantly different covariates
between the Magmaris and Orsiro groups in the unadjusted data
taken from the baseline and procedure characteristics. The variables in-
cluded in the MVA were: Orsiro stent, age, male gender, history of
smoking (previous and current), diabetes mellitus (with and without
insulin-therapy) unstable angina, ACC/AHA lesion characterization
(Types A, B1, B2 andC), pre- and post-procedure percentage of diameter
stenosis (%DS). The second step evaluated the interactions of the Orsiro
stent with all the covariates included in the 1st step. In order to control
Type I error rate, the statistical significance for the covariates interac-
tions was set at 0.01.., Comparison of clinical outcomes betweenMagmaris and Orsiro drug
ttps://doi.org/10.1016/j.ijcard.2019.11.003
Table 1
Baseline and procedure characteristics of the patients treated with Magmaris or Orsiro.
Magmaris group,
ITT
Orsiro group, ITT p-Value
N (total) % N (total) %
Baseline characteristics





























Non-insulin dependent 34(184) 18.5 66(290) 22.8 0.266
Insulin-dependent 12(184) 6.5 18(290) 6.2 0.891
History of smoking
Non-smoker 82(184) 44.6 92(290) 31.7 0.005
Previous smoker 30(184) 16.3 87(290) 30.0 b0.001
















Unstable angina 23(184) 12.5 58(298) 19.5 0.047
True bifurcation lesionsb 5(189) 2.6 4(330) 1.2 0.229
Target vessel
LMCA 0(189) 0.0 0(330) 0.0 –
LAD 78(189) 41.3 148
(330)
44.8 0.429
LCx 47(189) 24.9 73(330) 22.1 0.475




Type A 79(189) 41.8 87(330) 26.4 b0.001
Type B1 74(189) 39.2 150
(330)
45.4 0.163
Type B2 28(189) 14.8 46(330) 13.9 0.784
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3.1. Study population
The study population consisted of 482 patients (521 lesions). In the
Magmaris group, there were 184 patients (189 lesions), and in the
Orsiro group, there were 298 patients (332 lesions) (Fig. 1). The base-
line characteristics are listed in Table 1. The Magmaris group's mean
age was 65.5 ± 10.8 years, and in the Orsiro group, the mean age was
62.7 ± 10.4 years (p-value = 0.005). Male gender was 63.6% and
78.2% inMagmaris and Orsiro groups (p b 0.001), respectively. Unstable
anginawas 12.5% inMagmaris group compared to 19.5% in Orsiro group
(p=0.047). Previous smokers were 16.3% in Magmaris group vs. 30.0%
inOrsiro group (p b 0.001). Lesion classification by theAmerican College
of Cardiology/American Heart Association (ACC/AHA) type A was 41.8%
in Magmaris group vs. 26.4% in Orsiro group (p b 0.001), and Type C le-
sionswere 4.2% vs. 14.2% (p b 0.001) in theMagmaris andOrsiro groups,
respectively. A summary of procedure characteristics is also presented
in Table 1. Up to 6 months, all patients in both groups were taking
dual anti-platelet therapy (DAPT), while N6 months 58.7% of the
Magmaris group and 96.3% of the patients in Orsiro group were receiv-
ing DAPT (p b 0.001). Lesion lengthwas 12.4±5.0mm in theMagmaris
group and 13.3±6.7mm in theOrsiro group (p=0.117). The reference
vessel diameter (RVD) was 2.7 ± 0.4 mm and 2.8 ± 0.5 mm in the
Magmaris and Orsiro groups (p = 0.169), respectively. Pre-procedure
%DS was 54.8 ± 11.8% in the Magmaris group compared to 66.7 ±
14.3% in the Orsiro group (p b 0.001). Post-procedure %DS (in-segment)
was 19.6 ± 7.6% in theMagmaris group compared to 15.8± 6.8% in the
Orsiro group (p b 0.001).
3.2. Unadjusted Magmaris versus Orsiro clinical outcomes comparison
The unadjusted clinical outcomes of theMagmaris andOrsiro groups
at 12 months are listed in Supplemental Table 1. The primary compari-
son, which is TLF, revealed to be not significant between the groups,
6.0% in the Magmaris group vs. 6.4% in the Orsiro group (p = 0.869),
as presented in Fig. 2. In the secondary outcomes, neither the individual
components of the TLF nor the other clinical outcomes showed statisti-
cally significant differences between the Magmaris or Orsiro groups for
cardiac death (p = 0.640), target vessel MI (p = 0.783), CD-TLR (p =
0.268), death (p = 0.387), MI (p = 0.459), any TLR (p = 0.265), anyFig. 1. Flow diagram of the study.
Type C 8(189) 4.2 47(330) 14.2 b0.001
Procedure characteristics
Lesion length, mm (mean ± SD) 12.4 ±5.0 13.3 ±6.7 0.117
RVD, mm (mean ± SD) 2.7 ±0.4 2.8 ±0.5 0.169
Pre-procedure %DS (% ± SD) 54.8 ±11.8 66.7 ±14.3 b0.001
Post-procedure %DS (% ± SD) 19.6 ±7.6 15.8 ±6.8 b0.001
Abbreviations: %DS= percentage of diameter stenosis; ACC= American College of cardi-
ology; AHA = American Heart Association; CABG = coronary artery bypass grafting; ITT
= intention to treat; LMCA= left main coronary artery; LAD = left anterior descending
artery; LCx = left circumflex artery; MI = myocardial intervention; PCI = percutaneous
coronary intervention; RCA = right coronary artery; RVD = reference vessel diameter;
SD = standard deviation.
a PCI or CABG.
b True bifurcations were defined as Medina Classification 1.1.1, 0.1.1 and 1.0.1.
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there were no definite or probable ST cases in the Magmaris or Orsiro
groups.
3.3. Multivariate analysis
The covariates included in the first and second steps of the MVA
were age, male gender, diabetes, smoking status, unstable angina,
ACC/AHA lesion classification (types A, B1, B2 and C), pre- and post-
procedure percentage of diameter stenosis (%DS) assessed by Quantita-
tive Coronary Angiography (QCA), and device type (i.e. Orsiro stent). In., Comparison of clinical outcomes betweenMagmaris and Orsiro drug
ttps://doi.org/10.1016/j.ijcard.2019.11.003
Fig. 2. Kaplan-Meier survival estimates free of target lesion failure.
4 A. Hideo-Kajita et al. / International Journal of Cardiology xxx (xxxx) xxxTable 2, the MVA results are presented. After the adjustment of all co-
variates, there were no meaningful differences between the Magmaris
and Orsiro groups for the first and second steps (i.e. covariates and co-
variates interactions, respectively) of the multivariate analysis, albeit
the Orsiro stent revealed a TLF reduction of 24% in hazard function (p
= 0.533).
4. Discussion
This is the first report comparing the clinical outcomes between an
absorbable metal scaffold, like Magmaris, and Orsiro after 12 months.
There are 2 main findings from our analysis: [1] at 12 months, theTable 2








Orsiro stent 0.76 0.31–1.87 0.533
Age 0.99 0.95–1.03 0.662
Male gender 0.79 0.31–2.03 0.629
History of smoking
Previous 1.45 0.55–3.83 0.453
Current 2.01 0.70–5.75 0.193
Diabetes mellitus
Insulin 1.10 0.25–4.82 0.995
Non-insulin 1.19 0.25–4.87 0.705
Unstable angina 1.00 0.33–3.01 0.995
ACC/AHA lesion characterization
Type A 1.00 – –
Type B1 0.29 0.08–1.06 0.060
Type B2 0.64 0.22–1.81 0.396
Type C 0.50 0.13–1.93 0.316
Pre-procedure %DS 1.03 0.99–1.08 0.172
Post-procedure %DS 1.00 0.97–1.03 0.792
Covariates interactions
Orsiro stent vs. age – – 0.047
Orsiro stent vs. gender – – 0.617
Orsiro stent vs. smoking – – 0.806
Orsiro stent vs. diabetes – – 0.491
Orsiro stent vs. unstable angina – – 0.231
Orsiro stent vs. type A lesion – – 0.585
Orsiro stent vs. type B1 lesion – – 0.111
Orsiro stent vs. type B2 lesion – – 0.997
Orsiro stent vs. type C lesion – – 0.200
Orsiro stent vs. pre-procedure %DS – – 0.916
Orsiro stent vs. post-procedure %
DS
– – 0.745
Abbreviations: %DS= percentage of diameter stenosis; ACC= American College of cardi-
ology; AHA = American Heart Association; CI = confidence interval.
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nificant difference between the Magmaris or Orsiro groups, albeit after
adjustment of all other covariates, the MVA showed a non-significant
TLF reduction of 24% in hazard function for the Orsiro stent; and [2] nei-
ther Magmaris nor Orsiro presented any definite or probable ST case
after 12 months.
The adoption of DES in percutaneous coronary intervention consid-
erably decreased the in-stent restenosis rate in the majority of the cor-
onary artery disease clinical scenarios [16–18]. In SPIRIT trial, the TLF
rate between first- vs. second-generation DES over 12 months revealed
an important reduction of events in the patients of the second-
generation DES group [19]. Recently, Kandzari et al. in BIOFLOW V
trial showed a TLF rate of 6.0% in theOrsiro group vs. 10.0% in theXience
group (p = 0.030) after 12 months [10]. In the current study, the
Magmaris unadjusted TLF rate at 12 months was 6.0% with no relevant
differences as compared to the Orsiro DES.
On the other hand, in the Absorb III trial, Absorb (a polymeric BRS)
presented a TLF rate of 7.8% with a considerable difference (p =
0.007) against the Xience group (6.1%) over a year [20,21]. The Absorb
data showed a higher ST rate than second-generation DES over time
(1.5% vs. 0.7%, respectively) [19]. Wykrzykowska et al. reported in the
AIDA trial a 0.8% of late ST (Absorb group) and an accumulative definite
or probable ST rate at 2 years of 3.5% vs. 0.9% in the DES group [4]. In
contrast, neither Magmaris nor Orsiro unveiled any definite or probable
ST cases in the present study. These differences may come from the dif-
ference in scaffold platform design and composition.
In the metallic DES era, the second-generation DES late ST rate de-
creased from 4.90% to 0.50%–0.70% [1,2,20]. The Orsiro stent in the
BIOFLOW V trial showed a lower, but not significant (p = 0.700), defi-
nite or probable ST rate of 0.48% compared to the Xience (0.70%) at
12 months [10]. This lower rate can be partly attributed to the differ-
ences in strut thickness, abluminal biodegradable polymers, and
newer drugs, all of which together resulted in an overall improvement
of clinical outcomes in PCI patients [10,19,20]. In a sequence of pre-
clinical porcine shunt models, Otsuka et al., Waksman et al. and Lipinski
et al. explored the thrombogenecity of different device [22–24]. Otsuka
et al. performed an acute thrombogenic test among second-generation
metallic DES, and Xience presented better results compared to the
other devices [22];Waksman et al. showed a reduction of thrombus for-
mation and better endothelization by Magmaris compared to Absorb
and Xience [23]; and Lipinski et al. reported less acute thrombogenicity
inMagmaris group comparedwith a Stainless Steel Platformgroup [24].
DAPT duration in BIOFLOW-II, BIOSOLVE-II and -III trials followed
DAPT guideline recommendations of 6 months in stable CAD and
12 months acute coronary syndrome patients (ACS), still in use [25].
Through 6 months, all included patients in this pooled analysis had
DAPT. From 6 to 12months the DAPT duration was left to treating phy-
sician discretionwho according to the clinical presentation (ACS vs non-
ACS) extended it through 12 months.
In many dedicated clinical trials, the use of invasive intracoronary
imaging to guide PCI resulted in better clinical outcomes, mostly by re-
duction of acute and subacute ST [26,27]. In this pooled analysis which
included trials that usedMagmaris and Orsiro devices, the implantation
technique did not require invasive imaging guidance, only standard
angiography-based PCI technique. In the BIOSOLVE-II trial, Magmaris
invasive imaging acquisition was performed after implantation of the
device, with the purpose of follow-up its resorption process [6,7,28].
Lastly, a Weibull proportional hazards regression analysis was per-
formed, taking into account device type (i.e.Magmaris scaffold or Orsiro
stent) and age (i.e. 55, 65 and 75 years) (Supplemental Fig. 1). The
Magmaris group presented better outcomes in patients with 65 and
75 years and worst outcomes in younger patients (55 years) compared
the Orsiro group that presented more TLF-free patients among the
younger patients than in the older patients. These observations are hy-
pothesis generating and warrant future randomized comparisons be-
tween the two devices.., Comparison of clinical outcomes betweenMagmaris and Orsiro drug
ttps://doi.org/10.1016/j.ijcard.2019.11.003
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First, this is a comparison between 1 randomized controlled trial and
2 single-arm registries. Second, the study compared Magmaris and a
2nd generation DES (Orsiro), which were tested in two different trials.
As such, this analysis may be biased in regard to the selection of the pa-
tients. A sophisticated statistical analysis was performed to account for
this, although some residual confounding factors cannot be excluded.
Third, BIOSOLVE-II and -III trials treated less complex lesions. Forth, al-
though we used the largest study datasets suitable for this comparison,
this study may be underpowered for main effects. Finally, pooling data
from different studies introduces an additional source of error that po-
tentially affects the results/conclusions. One way to account for this is
to include “study” in the analysis as a random effect. We have included
sites within countries as random effects in our analyses because the
BIOSOLVE and BIOFLOW studies themselves obtained data from differ-
ent health care systems (countries) and different health care centers
(sites).
6. Conclusion
At 12 months, there were no significant differences between the
Magmaris and Orsiro groups for the unadjusted TLF assessment or the
covariates multivariate analysis. Over a year, there were no definite or
probable ST cases in the Magmaris or Orsiro groups. Lastly, the perti-
nence of the findings of the current analysis need to be seen in a bigger
context, the results should be taken as hypothesis generating and there-
after confirmed with a larger cohort in a randomized controlled trial.
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